The Path to Clinical Implementation of DPYD Pharmacogenetic Testing: Long-Term Experience from an External Quality Assessment Provider and a University Testing Center
The integration of DPYD testing into national guidelines has significantly increased its clinical adoption, enhancing patient safety in oncology. However, standardization challenges remain. Further harmonization of guidelines and expansion of PGx testing may further optimize chemotherapy safety in the future. .
Authors
- Volker Ast (ORCID: https://orcid.org/0009-0008-7318-0301)
- Ralf‐Dieter Hofheinz (ORCID: https://orcid.org/0000-0001-5972-8504)
- Maren Hedtke (ORCID: https://orcid.org/0000-0002-2162-7588)
- Verena Haselmann (ORCID: https://orcid.org/0000-0002-8380-6581)
- Michael Neumaier (ORCID: https://orcid.org/0000-0003-0410-3931)
- Anja Keßler
- Johannes Leidheiser
Institutions
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- Reference Institute for Bioanalytics (DE)
- University Medical Centre Mannheim (DE)
Publication Details
- Journal
- Oncology Research and Treatment
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1159/000546912
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00